# Topical Acne Products

This is a subcategory of Central Nervous System (CNS) Agents.

## Formulary

### Preferred

| Preferred                             |
| :------------------------------------ |
| Adapalene Gel 0.1% AR                 |
| Azelex Cream                          |
| Benzoyl Peroxide                      |
| Clindamycin Gel                       |
| Clindamycin Lot                       |
| Clindamycin Sol                       |
| Clindamycin/Benzoyl Peroxide          |
| Erythromycin                          |
| Erythromycin/Benzoyl Peroxide         |
| Neuac                                 |
| Sodium Sulfacetamide                  |
| Sodium Sulfacetamide/Sulfur Cream     |
| Sodium Sulfacetamide/Sulfur Wash Susp |
| Tretinoin AR                          |

### Non-Preferred

| Non-Preferred                   |
| :------------------------------ |
| Adapalene Cream, Sol 0.1% AR    |
| Adapalene Gel 0.3% AR           |
| Adapalene/Benzoyl Peroxide AR   |
| Aklief AR                       |
| Altreno AR                      |
| Amzeeq                          |
| Arazlo AR                       |
| Azelaic Acid Gel                |
| Benzoyl Peroxide Foam           |
| Clindacin Kit                   |
| Clindamycin Foam                |
| Clindamycin Swabs               |
| Clindamycin/Tretinoin AR        |
| Dapsone Gel                     |
| Finacea Foam                    |
| Onexton Gel                     |
| Ovace Plus                      |
| Plixda AR                       |
| Sodium Sulfacetamide/Sulfur Gel |
| Sodium Sulfaetamide Pads        |
| Tazarotene Cream 0.1% AR        |
| Tazarotene Foam 0.1% AR         |
| Twyneo AR                       |
| Winlevi                         |

## Length of Authorizations

365 Days

**All Authorizations**

Must be prescribed in accordance with FDA approved labeling

## Additonal Criteria

### Non-Preferred

-   Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) **OR**
    -   For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation
-   Must have had an inadequate clinical response of at least **30 days** (or **90 days** for retinoids) of at least **three preferred** drugs
    -   For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)
    -   For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)

### Tretinoin/Benzoyl Peroxide

Additional Tretinoin/Benzoyl Peroxide (Twyneo) Criteria

-   Must provide documentation for patient’s inability to use the individual drugs

### Additional Information

-   All retinoids – May be authorized with a diagnosis of skin cancer
-   Tazarotene (Tazorac) – May be authorized with a diagnosis or psoriasis

### Subsequent Authorization

-   Must provide documentation of patient’s clinical response to treatment and ongoing safety monitoring

**AR**- All topical retinoids: a PA is required for patients 24 years and older

## Links

[Criteria](https://pharmacy.medicaid.ohio.gov/sites/default/files/20221001_UPDL_Criteria_APPROVED.pdf#page=47)

[Preferred Drug List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20221001_UPDL_APPROVED_.pdf#page=19)
